Harrow Health, Inc.
$33.32
+1.4%Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -238.0).
Valuation inputs: P/E -238.0, earnings yield N/A, momentum +1.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -9.8%, ROIC +12.0%).
Profitability stack: net margin -1.9%, ROE -9.8%, ROIC +12.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +87.0%, momentum +1.4%, net margin -1.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Harrow Health, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Harrow Health, Inc. Fair Value Envelope
Harrow Health, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Harrow Health, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Harrow Health, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Harrow Health, Inc. Street Expectations Map
Wall Street analysts project that HROW stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 73.67, with estimates ranging from a low of 63.00 to a high of 88.00.
The consensus 1-year price target stands at 73.67, with estimates ranging from a low of 63.00 to a high of 88.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Harrow Health, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.64M and sold $11.53M worth of HROW shares, resulting in $9.89M of net selling activity.
3 Months
15.5K
468.72K
0
0.00
+469K
+$469K
3-6 Months
0
0.00
218.0K
8.96M
-9.0M
-$8.96M
6-9 Months
0
0.00
33.0K
1.59M
-1.6M
-$1.59M
9-12 Months
30.0K
1.17M
32.0K
977.73K
+192K
+$192K
Top Buyers
Pollard Randall E.
Officer: Chief Accounting Officer
$1.17M
Baum Mark L
Director, Officer: Chief Executive Officer
$302K
Boll Andrew R.
Officer: President And Cfo
$105K
Graves Adrienne L
Director
$31K
Silvernail Lauren P
Director
$31K
Top Sellers
Opaleye Management Inc.
10 Percent Owner
$9.94M
Mullery Francis William Jr
Officer: Ceo, Imprimisrx
$1.59M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $9.89M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
hrow Dividend History
Learning Layer
Related Guides
Build conviction on HROW by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.